Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $8.75 Average Price Target from Brokerages

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has received a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $8.75.

Several brokerages recently issued reports on AUTL. Needham & Company LLC reiterated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, April 9th. Weiss Ratings raised Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 6th. Jefferies Financial Group upgraded Autolus Therapeutics to a “strong-buy” rating in a report on Monday, April 20th. Truist Financial raised Autolus Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, HC Wainwright increased their price objective on Autolus Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, May 14th.

Autolus Therapeutics Stock Down 4.7%

Shares of AUTL traded down $0.08 during trading hours on Tuesday, reaching $1.61. The company’s stock had a trading volume of 1,348,300 shares, compared to its average volume of 930,621. The company has a 50 day moving average of $1.62 and a two-hundred day moving average of $1.56. The firm has a market cap of $428.52 million, a price-to-earnings ratio of -1.48 and a beta of 2.04. Autolus Therapeutics has a 1-year low of $1.18 and a 1-year high of $2.70.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02. The firm had revenue of $26.22 million for the quarter, compared to analyst estimates of $26.27 million. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. As a group, analysts forecast that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Mak Capital One LLC boosted its holdings in Autolus Therapeutics by 15.3% in the fourth quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock worth $59,711,000 after purchasing an additional 3,987,727 shares in the last quarter. Armistice Capital LLC raised its stake in shares of Autolus Therapeutics by 12.2% in the 4th quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock valued at $34,825,000 after acquiring an additional 1,900,000 shares in the last quarter. Schroder Investment Management Group lifted its holdings in Autolus Therapeutics by 12.5% in the 4th quarter. Schroder Investment Management Group now owns 9,489,345 shares of the company’s stock worth $18,694,000 after purchasing an additional 1,056,092 shares during the last quarter. Bank of America Corp DE boosted its position in Autolus Therapeutics by 108.1% during the third quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock worth $3,308,000 after purchasing an additional 1,054,458 shares during the period. Finally, Cetera Investment Advisers grew its holdings in Autolus Therapeutics by 2.7% during the first quarter. Cetera Investment Advisers now owns 1,129,074 shares of the company’s stock valued at $1,558,000 after purchasing an additional 29,324 shares during the last quarter. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.